Related Experiment Video
Updated: Nov 18, 2025
05:51
Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
Published on: October 14, 2021
4.1K
Clinical Trial for Parkinson's Disease Gets a Green Light in the US
1Department of Clinical Application, Center for iPS Cell Research and Application, Kyoto University, Kyoto 606-8507, Japan.
Cell Stem Cell
|February 5, 2021
Abstract:
Cell-based therapy is expected as an alternative treatment for Parkinson's disease. In this issue of Cell Stem Cell, two accompanying papers (Kim et al., 2021; Piao et al., 2021) report the induction of clinically applicable dopaminergic neurons from human embryonic stem cells and the results of pre-clinical study toward a clinical trial.
Insights
Cell-based therapy offers a promising alternative for Parkinson's disease treatment. Researchers successfully generated clinical-grade dopaminergic neurons from human embryonic stem cells, advancing pre-clinical studies for future trials.
Area of Science:
- Neuroscience
- Stem Cell Biology
- Regenerative Medicine
Background:
- Parkinson's disease (PD) is a neurodegenerative disorder characterized by the loss of dopaminergic neurons.
- Current treatments for PD manage symptoms but do not halt disease progression.
- Cell-based therapy presents a potential disease-modifying strategy for PD.
Purpose of the Study:
- To induce clinically applicable dopaminergic neurons from human embryonic stem cells (hESCs).
- To evaluate the efficacy and safety of these induced neurons in pre-clinical models of Parkinson's disease.
- To assess the potential for translating this cell therapy approach into human clinical trials.
Main Methods:
- Directed differentiation of hESCs to generate dopaminergic progenitor cells.
- Purification and expansion of dopaminergic neuron precursors.
- Transplantation of differentiated neurons into pre-clinical models of Parkinson's disease.
- Assessment of graft survival, neuronal function, and behavioral recovery.
Main Results:
- Successful generation of large quantities of clinical-grade dopaminergic neurons from hESCs.
- Demonstrated integration and functional recovery in pre-clinical models.
- Pre-clinical studies indicate the potential for a safe and effective cell therapy for Parkinson's disease.
Conclusions:
- Human embryonic stem cell-derived dopaminergic neurons are a viable source for cell replacement therapy in Parkinson's disease.
- These findings pave the way for future clinical trials investigating this novel therapeutic approach.
- Cell-based therapies hold significant promise for treating neurodegenerative conditions like Parkinson's disease.
Related Concept Videos
01:24Parkinson's Disease: Treatment
756
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
756
01:11Clinical Trials: Overview
4.3K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.3K
01:16Clinical Trials
10.0K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
10.0K
01:15Parkinson's Disease: Overview
1.2K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.2K
01:26FDA Approved Drugs: Changes to Approved Drugs
80
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
80
01:28Preclinical Development: Overview
5.5K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.5K